Bausch Health Companies (BHC) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Bausch Health Companies (BHC) over the past year, gaining 57.5% versus a loss of 5.5%. Over five years, PCRX leads with a -31.7% price change compared with -78.8% for BHC. Bausch Health Companies is the larger company by market cap ($2.26 billion vs $1.45 billion), about 1.6 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.4x vs 10.5x for Pacira BioSciences). Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus 1.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | PCRX |
|---|---|---|
| Share price | $6.04 | $36.31 |
| Market cap | $2.26B | $1.45B |
| 1-day change | 0.00% | -0.22% |
| YTD return | -13.09% | +40.30% |
| 1-year return | -5.48% | +57.46% |
| 5-year return | -78.80% | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | 1.44 | 10.50 |
| EPS (TTM) | $-2.95 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $726.41M |
| Revenue growth (YoY) | +6.66% | +3.63% |
| Net income (latest FY) | $157.00M | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | 17.66% | 2.64% |
| Net margin | 1.53% | 0.97% |
| 52-week high | $8.00 | $36.46 |
| 52-week low | $4.33 | $18.80 |
| Distance from 52-week high | -24.50% | -0.41% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +24.17% | -17.08% |
| Average volume | 3.27M | 1.03M |
| Shares outstanding | 373.99M | 39.91M |
| Employees | 20,300 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed BHC by 62.9 percentage points over the past year.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
BHC vs PCRX FAQ
Which is bigger, Bausch Health Companies or Pacira BioSciences?
Bausch Health Companies (BHC) is larger, with a market capitalization of $2.26B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, BHC or PCRX?
PCRX returned +57.46% over the past 12 months, compared with -5.48% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.